Treatment of sepsis with TAFI
AssigneeOklahoma Medical Research Foundation
InventorsFletcher B. Taylor JR., Laszlo Bajzar
Life of this patent
Estimating the term…
Abstract
A method for inhibiting and for reversing the dysfunctional response of vascular endothelial cells to an inflammatory stimulus in a subject in need of such therapy has been developed in which an effective amount of a pharmaceutical composition comprising thrombin-activatable fibrinolysis inhibitor (TAFI) combined with a pharmaceutically acceptable carrier and optionally other treatments is administered to the subject.
Claims19
A method for treating or preventing a disorder associated with dysfunctional endothelium comprising administering to a patient in need thereof an effective amount of thrombin-activatable fibrinolysis inhibitor to alleviate symptoms of the disorder.
A composition for treating or preventing a disorder associated with dysfunctional endothelium comprising an effective amount of a thrombin-activatable fibrinolysis inhibitor to alleviate the symptoms of the disorder.
A kit comprising thrombin-activatable fibrinolysis inhibitor and activated protein C for administration to a patient in need thereof.
Dependencies are inferred from the claim text.